Chin B. Eap, PhD, is affiliated with multiple institutions in Switzerland, including the Unit of Pharmacogenetics and Clinical Psychopharmacology at Lausanne University Hospital and the University of Geneva. Eap has published extensively on metabolic disorders related to psychiatric treatment, focusing on weight changes, cardiometabolic risk, and lipid disturbances in patients with bipolar disorder, psychotic disorders, and schizophrenia/schizoaffective disorders. The research includes studies on the effects of psychotropic drugs such as valproate and risperidone on metabolic parameters. Eap's work has appeared in Psychiatrist.com from 2015 to 2024.
1 Read counts for articles published before 2020 may include some non-human traffic.
2 Citation counts provided by Crossref.
Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.
